04/20/21 8:30 AMOTC : CSLLYSeqirus Publishes New Real-World Evidence Supporting the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Clinical Infectious DiseasesSeqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's MF59 (R) adjuvanted, trivalent influenza vaccine (aTIV) in the peer-reviewed medical journal Clinical Infectious Diseases. 1RHEA-AIneutral
04/19/21 5:00 PMOTC : CSLLY, TRUMYTerumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection PlatformTerumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis deviceRHEA-AIneutral
03/25/21 8:30 AMOTC : CSLLYNew Seqirus Data Published in Vaccines Highlight Effectiveness and Economic Benefit of Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) in the 2018/19 U.S. Influenza SeasonSeqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's cell-based quadrivalent seasonal influenza vaccine (QIVc) in peer-reviewed medical journal Vaccines. 1 This retrospectiveRHEA-AIneutral
03/05/21 8:30 AMOTC : CSLLYSeqirus Announces U.S. FDA Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and OlderSeqirus, a global leader in influenza prevention, today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX (R) QUADRIVALENT (Influenza Vaccine), the company's cell-based quadrivalent influenza vaccine (QIVc), for an expandedRHEA-AIneutral
09/28/20 8:10 AMOTC : CSLLYU.S. Food and Drug Administration Approves HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric PatientsCSL Behring, a global biotherapeutics leader, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HAEGARDA (R) (C1 Esterase Inhibitor Subcutaneous [Human]) for routine prophylaxis to preventRHEA-AIvery positive
09/21/20 8:30 AMOTC : CSLLYSeqirus Publishes New Real-World Evidence (RWE) on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in VaccinesSeqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) that demonstrated an MF59 (R) adjuvanted, trivalent influenza vaccine (aTIV) was more effective than a standard-dose non-adjuvanted trivalentRHEA-AIneutral
09/16/20 8:30 AMOTC : CSLLYSeqirus Real World Evidence Published in Vaccine Highlights Value of Cell-Based Quadrivalent Influenza Vaccine in Preventing Influenza Related Hospitalizations in the U.S. 2017/18 SeasonSeqirus, a global leader in influenza prevention, today announced the publication of real-world evidence (RWE) on the company's cell-based quadrivalent influenza vaccine (QIVc) in peer-reviewed medical journal Vaccine. Study results indicate QIVc wasRHEA-AIneutral
